ArticleEBioMedicine2019
Role of CXCR3 signaling in response to anti-PD-1 therapy.
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Oropharyngeal cancer and human papillomavirus: a visualization based on bibliometric analysis and topic modeling.Frontiers in microbiology · 2024Pooled it
- Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.Nature communications · 2024Trial
- A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.Neuro-oncology · 2024Trial
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
- Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.Journal of translational medicine · 2026Article
- Article
- T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges.The Journal of clinical investigation · 2026Article
- IFI44L modulates chemoradiotherapy sensitivity and CD8Frontiers in oncology · 2026Article
- Subtype-specific genetic drivers of immune evasion in breast cancer.Immuno-oncology technology · 2025Article
- Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma.Scientific reports · 2025Article
- Establishment and validation of a prognostic model based on vasculogenic mimicry-related gene clustering in ovarian cancer.Frontiers in oncology · 2025Article
- Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge.International journal of molecular sciences · 2024Review
- Review
- Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis.Cancer cell · 2024Article
- Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy.Cancer immunology research · 2024Article
- Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation.Cell proliferation · 2024Article
- CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils.Journal of hepatocellular carcinoma · 2024Article
- Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses.Oncoimmunology · 2024Article
- Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.Cancer immunology, immunotherapy : CII · 2023Article
- CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.Cancer immunology, immunotherapy : CII · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor mutations and tumor microenvironment are associated with resistance to cancer immunotherapies. However, peripheral T cell in effective anti-programmed death 1 (PD-1) antibody treatment is poorly understood.
methodsMass spectrometry and conventional flow cytometry were used to investigate peripheral blood cells isolated from patients. Furthermore, melanoma mouse model was performed to assess the role of CXCR3 signaling in anti-PD-1 antibody treatment.
findingsWe revealed a marked increase in the percentage of CXCR3
interpretationThe dynamic changes in CXCR3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.